TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00726544

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ARC 1779 Placebo
Description: ARC1779 Injection or placebo is administered intravenously to patients as an initial loading dose followed by continuous infusion of up to 14 days plus 2 day taper.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARC1779 Injection
Description: ARC1779 Injection or placebo is administered intravenously to patients as an initial loading dose followed by continuous infusion of up to 14 days plus 2 day taper. Treatment with ARC1779 Injection is to be given at low dosage that is intended to produce target steady-state ARC1779 plasma concentrations during infusion of 3μg/mL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARC1779 Injection
Description: ARC1779 Injection or placebo is administered intravenously to patients as an initial loading dose followed by continuous infusion of up to 14 days plus 2 day taper. Treatment with ARC1779 Injection is to be given at low dosage that is intended to produce target steady-state ARC1779 plasma concentrations during infusion of 6μg/mL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARC1779 Injection
Description: ARC1779 Injection or placebo is administered intravenously to patients as an initial loading dose followed by continuous infusion of up to 14 days plus 2 day taper. Treatment with ARC1779 Injection is to be given at low dosage that is intended to produce target steady-state ARC1779 plasma concentrations during infusion of 12μg/mL.
Study: NCT04293562

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Correlative studies
Study: NCT01576952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISV-303
Description: Bromfenac in DuraSite

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: DuraSite Vehicle
Description: DuraSite Vehicle
Study: NCT02748486

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive Training Jumping to Conclusion
Description: Therapeutical intervention based on cognitive-behavioural therapy paradigm. Addresses cognitive bias of schizophrenia patients - jumping to conclusion.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Group discussion
Description: Group discussion of current events

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive Training To Empathize
Description: Therapeutical intervention based on cognitive-behavioural therapy paradigm. Addresses cognitive bias of schizophrenia patients - Theory of Mind deficits.
Study: NCT01803139

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adjuvant breast radiotherapy
Description: Adjuvant radiotherapy delivering 50 Gy in 25 treatments, with an additional boost dose of 16 Gy at the discretion of the radiation oncologist.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant breast radiotherapy
Description: Adjuvant radiotherapy delivering 50 Gy in 25 treatments, with an additional boost dose of 16 Gy at the discretion of the radiation oncologist.
Study: NCT01763970

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Study: NCT02541188

Intervention type: GENETIC
Intervention: Genetic analysis

Intervention type: GENETIC
Intervention: Genetic analysis
Study: NCT00838253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istaroxime
Description: Istaroxime 0.5 μg/kg/min (30 μg/kg/h) continuous i.v. infusion for 24 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istaroxime
Description: Istaroxime 1.0 μg/kg/min (60 μg/kg/h) continuous i.v. infusion for 24 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istaroxime
Description: Istaroxime 1.5 μg/kg/min (90 μg/kg/h) continuous i.v. infusion for 24 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo continuous i.v. infusion for 24 hours
Study: NCT04470401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA
Description: application of 1cc of placebo (saline) or 1cc of abobotulinumtoxinA in both subscapularis and pectoral major muscles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: application of 1cc of placebo (saline) or 1cc of abobotulinumtoxinA in both subscapularis and pectoral major muscles
Study: NCT04293562

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo BM aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo BM aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo BM aspiration
Study: NCT02359370

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine 2 mg/kg was administered through continuous infusion, immediately before induction of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulphate
Description: Magnesium Sulphate 30 mg/kg was administered through continuous infusion, immediately before induction of anesthesia
Study: NCT02093312

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Home food-delivery service
Description: A home food-delivery service is offered the intervention group of cancer patients
Study: NCT00371085

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education
Description: Video-based educational program for heart failure focus on daily weights, medication taking, and salt restriction
Study: NCT02434744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KD026
Description: Dosed in combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KD026
Description: Dosed in combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KD026
Description: Dosed in combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KD026
Description: Dosed in combination

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosed in combination

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosed in combination

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosed in combination

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosed in combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Drug prescribed by each subject's prescribing physician

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Drug prescribed by each subject's prescribing physician

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Drug prescribed by each subject's prescribing physician

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Drug prescribed by each subject's prescribing physician

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Drug prescribed by each subject's prescribing physician

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Drug prescribed by each subject's prescribing physician

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Drug prescribed by each subject's prescribing physician

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Drug prescribed by each subject's prescribing physician
Study: NCT03631550

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Relivion active
Description: 1 hour self-administered occipital and supraorbital transcutaneous nerve stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Relivion Sham
Description: 1 hour self-administered Sham occipital and supraorbital transcutaneous nerve stimulation
Study: NCT04581850

Intervention type: BEHAVIORAL
Intervention: Sleep recording
Description: Sleep is recorded at home during 7 nights in a row using a connected headband. The participant also has to fill in a sleep agenda every day.

Intervention type: BEHAVIORAL
Intervention: Sleep recording
Description: Sleep is recorded at home during 7 nights in a row using a connected headband. The participant also has to fill in a sleep agenda every day.

Intervention type: BEHAVIORAL
Intervention: Cognitive tasks
Description: Working memory and inhibition capacity is assessed during computer-based tasks (2-back and Go/No-Go tasks) at enrollment and 1 month after enrollment.

Intervention type: BEHAVIORAL
Intervention: Cognitive tasks
Description: Working memory and inhibition capacity is assessed during computer-based tasks (2-back and Go/No-Go tasks) at enrollment and 1 month after enrollment.

Intervention type: OTHER
Intervention: Questionnaires
Description: The participant has to fill in several questionnaires at enrollment and 1 month after enrollment in order to assess:~* PTSD severity~* chronotype~* Sleep quality~* Daytime sleepiness~* Mood state~* Depression~* Mental disorders and their consequences

Intervention type: OTHER
Intervention: Questionnaires
Description: The participant has to fill in several questionnaires at enrollment and 1 month after enrollment in order to assess:~* PTSD severity~* chronotype~* Sleep quality~* Daytime sleepiness~* Mood state~* Depression~* Mental disorders and their consequences
Study: NCT03314675

Intervention type: DEVICE
Group type: OTHER
Intervention: BIOTRONIK CRT-D
Description: Pre-specified follow-up and measurements
Study: NCT03062358

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Administered as an intravenous (IV) infusion every 3 weeks (Q3W)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Normal saline solution administered as an IV infusion Q3W
Study: NCT03349528

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Probiotic Supplement
Description: Probiotic supplement 1 tablet by mouth daily

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Inert Compound
Description: Probiotic identical placebo 1 tablet by mouth daily
Study: NCT03256422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment discontinuation
Description: • Receiving tritherapy. Allowed treatment drugs are :~1. nucleoside analogs : tenofovir (TDF ou TAF), emtricitabine, abacavir, lamivudine~2. protease inhibitors : lopinavir/r, darunavir/r ou atazanavir/r~3. non nucleoside reverse transcriptase inhibitors : efavirenz, rilpivirine ou etravirine~4. integrase inhibitors : dolutegravir, elvitegravir/cobicistat ou raltegravir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment discontinuation
Description: • Receiving tritherapy. Allowed treatment drugs are :~1. nucleoside analogs : tenofovir (TDF ou TAF), emtricitabine, abacavir, lamivudine~2. protease inhibitors : lopinavir/r, darunavir/r ou atazanavir/r~3. non nucleoside reverse transcriptase inhibitors : efavirenz, rilpivirine ou etravirine~4. integrase inhibitors : dolutegravir, elvitegravir/cobicistat ou raltegravir
Study: NCT04161183

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracoporeal shock wave therapy
Description: Probe be transcutaneous applied to the region of bladder dome, right upper lateral wall, right lower lateral wall, left upper lateral wall, and left lower lateral wall with 2500 shocks, frequency of 4 pulses per second and maximum total energy flow density 0.25 millijoule/mm2 once a week for 6 weeks

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Probe be transcutaneous applied to the region of bladder dome, right upper lateral wall, right lower lateral wall, left upper lateral wall, and left lower lateral wall with 2500 shocks, frequency of 4 pulses per second but no energy once a week for 6 weeks
Study: NCT04209010

Intervention type: PROCEDURE
Intervention: one-stage technique
Description: breast reconstruction in one stage using silicone implant and acellular dermal matrix.
Study: NCT03478228

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-Sensory Training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multi-Sensory Training
Study: NCT04293562

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo BM aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo BM aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo BM aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo BM aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo BM aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo BM aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo BM aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo BM aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo BM aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo BM aspiration
Study: NCT03062358

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: best supportive care (BSC)
Description: BSC will include pain management and management of other potential complications including ascites per local standards of care.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: best supportive care (BSC)
Description: BSC will include pain management and management of other potential complications including ascites per local standards of care.
Study: NCT04293562

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo BM aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: BM biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: BM biopsy
Study: NCT04512651

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tibiotarsal Thrust Manipulation
Description: The dancers were positioned in dorsal decubitus position with the heel outside the stretcher. The osteopath positioned in a lateral feint, inflected knees and forearms in the same plane as the participant's leg. With the internal hand slipped the pinky finger on the medial edge of the foot to the talus neck, the other fingers on the dorsum of the foot and the thumbs controlling the first metatarsus. The position of the talus in relation to the tibia was corrected, initially by placing the foot in eversion and then in dorsal flexion. The osteopath left the body weight behind, causing a traction in the joint. The thrust consisted of a impulse of high speed and low amplitude impulse in a caudal direction, closing the elbows20. The technique was performed until the obtainment (achieved) the joint noise only in the restricted foot, and only one service was performed. After one week, a reassessment of the painful sensation after the dance was performed.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Simulation Tibiotarsal Thrust Manipulation
Description: Simulation of the technique Tibiotarsal Thrust Manipulation, with the participants and the osteopath positioned in the same way as the IG, however there was no reproduction of joint noise.
Study: NCT02869022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Custodiol-N
Description: comparison of two Solutions, Custodiol-N versus Custodiol, for organ Perfusion in heart transplantation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Custodiol
Description: comparison of two Solutions, Custodiol-N versus Custodiol, for organ Perfusion in heart transplantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: organ perfusion for heart transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: organ perfusion for heart transplantation
Study: NCT01170962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052
Description: Film coated tablet, Oral, 20 mg, once daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052
Description: Film coated tablet, Oral, 20 mg, once daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052
Description: Film coated Tablet, Oral, 60 mg, once daily (divided dose taken BID), 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052
Description: Film coated Tablet, Oral, 60 mg, once daily (divided dose taken BID), 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Film coated tablet, Oral, 0mg, Once daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a
Description: Solution for injection, Subcutaneous injection, 180 µg, weekly, 24 or 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a
Description: Solution for injection, Subcutaneous injection, 180 µg, weekly, 24 or 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a
Description: Solution for injection, Subcutaneous injection, 180 µg, weekly, 24 or 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a
Description: Solution for injection, Subcutaneous injection, 180 µg, weekly, 24 or 48 weeks
Study: NCT01005706

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rapamune, mycophenolate mofetil and steroid
Description: At the time of transition patients randomized into this arm of the study will receive loading doses of sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml.~Patients randomized into this arm of the study will continue their current dosing regimen and frequency of mycophenolate mofetil. Serum trough level monitoring of mycophenolic acid will not be performed unless clinically warranted per standard of care and dosage adjustments from such levels will be made only with consent of the study primary investigator.
Study: NCT01170962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a
Description: Solution for injection, Subcutaneous injection, 180 µg, weekly, 24 or 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: Film coated tablet, Oral, 1,000 or 1,200 mg based on weight, divided dose taken twice a day (BID), 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: Film coated tablet, Oral, 1,000 or 1,200 mg based on weight, divided dose taken twice a day (BID), 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: Film coated tablet, Oral, 1,000 or 1,200 mg based on weight, divided dose taken twice a day (BID), 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: Film coated tablet, Oral, 1,000 or 1,200 mg based on weight, divided dose taken twice a day (BID), 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: Film coated tablet, Oral, 1,000 or 1,200 mg based on weight, divided dose taken twice a day (BID), 48 weeks
Study: NCT03956004

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OM1 Dell Shared Decision Making Tool
Description: Decision aid meant to improve shared decision making among patients and providers.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education material from OM1 Dell Shared Decision Making Tool
Description: Investigator-written educational material and quiz to test knowledge of osteoarthritis and treatment options.
Study: NCT03887650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivicaine 1.3%
Description: 10mL Liposomal Bupivacaine 1.3% (133 mg) mixed with 10mL of 0.5% Bupivacaine (total volume 20mL) in single injection interscalene brachial plexus block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.5%
Description: 20mL 0.5% Bupivacaine with 5 mg PF dexamethasone and 5 mcg epinephrine (total volume 20.5mL) in single injection interscalene brachial plexus block
Study: NCT01503749

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-colony stimulating factor
Description: G-colony stimulating factor (5ug/kg/day)will be administered subcutaneously to three patients with liver cirrhosis of this arm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infusion of the mobilized monocyte cells
Description: G-colony stimulating factor (5ug/kg/day)will be administered twice subcutaneously for 3 days to three patients with liver cirrhosis of this arm. On the day 4th, leukapheresis will be done to collect peripheral blood mononucleated cells. And then we are going to infuse the collected peripheral blood mononucleated cells of their own through the portal vein of each patients under ultrasonographic guidance.